Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Roberts

Showing results (161-170 of 186) with videos related to

Pageof 19
Sort By:
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trialPedro M Folegatti, Mustapha Bittaye, Amy Flaxman, et al.
The Journal of Infectious Diseases|November 9, 2018
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalNavin Venkatraman, Birahim Pierre Ndiaye, Georgina Bowyer, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
Lancet (London, England)|February 4, 2024
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S Datoo, Alassane Dicko, Halidou Tinto, et al.
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
JCI Insight|June 15, 2017
Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodiesRuth O Payne, Sarah E Silk, Sean C Elias, et al.
Lancet (London, England)|May 8, 2021
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trialMehreen S Datoo, Magloire H Natama, Athanase Somé, et al.
The Lancet. Infectious Diseases|September 10, 2022
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trialMehreen S Datoo, Hamtandi Magloire Natama, Athanase Somé, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2026
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experienceFrancis Proulx-Rocray, Rebecca Symons, Yang Wang, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Pageof 19

Showing results (161-170 of 186) with videos related to

Sort By:
Pageof 19
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trialPedro M Folegatti, Mustapha Bittaye, Amy Flaxman, et al.
The Journal of Infectious Diseases|November 9, 2018
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalNavin Venkatraman, Birahim Pierre Ndiaye, Georgina Bowyer, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
Lancet (London, England)|February 4, 2024
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S Datoo, Alassane Dicko, Halidou Tinto, et al.
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
JCI Insight|June 15, 2017
Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodiesRuth O Payne, Sarah E Silk, Sean C Elias, et al.
Lancet (London, England)|May 8, 2021
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trialMehreen S Datoo, Magloire H Natama, Athanase Somé, et al.
The Lancet. Infectious Diseases|September 10, 2022
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trialMehreen S Datoo, Hamtandi Magloire Natama, Athanase Somé, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2026
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experienceFrancis Proulx-Rocray, Rebecca Symons, Yang Wang, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Pageof 19